A systemic cause of patient harm could be better avoided with the help of technology, following the launch of Miya Results Tracking by health tech company Alcidion.
The new digital solution is designed to reduce the risk of test results not being followed up. It has been built to help healthcare professionals in hospital settings to more easily visualise, prioritise and acknowledge high volumes of tests results generated for patients every day, and to take appropriate action in a timely manner.
Divergent thinking is characterized by the ability to generate a unique solution to a question that does not have one expected solution, such as "What is the best way to avoid talking about politics with my parents?"
Publishing online March 6 in the Journal of Medical Internet Research, the study examined the capabilities of a form of artificial intelligence called generative AI or GenAI, which predicts likely options for the next word in any sentence based on how billions of people used words in context on the internet.
EMRAM - the Electronic Medical Record Adoption Model - assesses a health facility's adoption and maturity of its digital capabilities.
The RDS is a once-for-Scotland national project funded by the Scottish Government and run by Healthcare Improvement Scotland.
A Cancer Research UK-funded study reveals that prostate cancer, which affects one in eight men in their lifetime, includes two different subtypes termed evotypes.
For the 98 million adults who are prediabetic and at risk of developing Type II diabetes, preventive treatments such as the drug metformin can help stave off the disease.
Bayer moves ahead with advancements across its comprehensive Radiology portfolio as well as expanded offering in its digital business and services. The company announced that new clinical and pre-clinical data for gadoquatrane, Bayer's novel investigational macrocyclic gadolinium-based contrast agent currently in Phase III clinical development, will be presented at the 2024 European Congress of Radiology (ECR) - taking place from February 28 to March 3, 2024, in Vienna, Austria.